Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of genetic specialist Sequenom
So what: Sequenom announced that the American Journal of Obstetrics and Gynecology will publish a study showcasing the company's SensiGene T21 laboratory developed test. The paper, "Noninvasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood: a study in a clinical setting" (not exactly bathroom reading) was aimed at using the company's product for identifying trisomy 21 samples from a larger sample group. Trisomy 21 is a chromosomal abnormality more commonly known as Down syndrome.
Now what: The company is planning a larger clinical validation study for this year, but the initial results look very positive, since the test was able to correctly identify every T21 sample. Positive study results or not, though, Sequenom's stock remains very speculative as the company has yet to report a profit and continuously burns cash.
Want to keep up to date on Sequenom? Add it to your watchlist.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.
Fool contributor Matt Koppenheffer does not own shares of any of the companies mentioned. You can check out what Matt is keeping an eye on by visiting his CAPS portfolio, or you can follow Matt on Twitter @KoppTheFool or on his RSS feed. The Fool's disclosure policy prefers dividends over a sharp stick in the eye.